Journal
MUSCLE & NERVE
Volume 38, Issue 4, Pages 1236-1245Publisher
WILEY
DOI: 10.1002/mus.21025
Keywords
Pompe disease; glycogen storage disease type II; acid maltase deficiency; outcome measures; prospective cohort study
Categories
Funding
- Genzyme Corp., Cambridge, MA
- National Center for Research Resources (NCRR) [M01-RR-00037]
Ask authors/readers for more resources
The objective of this 12-month study was to describe the clinical features of late-onset Pompe disease and identify appropriate outcome measures for use in clinical trials. Assessments included quantitative muscle testing (QMT), functional activities (FAA), 6-min walk test (6MWT), and pulmonary function testing (PFT). Percent predicted values indicated quantifiable upper and lower extremity weakness, impaired walking ability, and respiratory muscle weakness. Significant declines in arm and leg strength and pulmonary function were observed during the study period. The outcome measures were demonstrated to be safe and reliable. Symptom duration was identified as the best predictor of the extent of skeletal and respiratory muscle weakness.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available